Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 25951-25960 Newer>

The Motley Fool September 6, 2007 Anders Bylund	ADC Turns to Fiber As copper turns obsolete, this nimble old-line telecom turns high-tech. The stock price may be up 47% over the last year, but it's down 93% from its bubbly peak in 2001.
The Motley Fool September 6, 2007 Ryan Fuhrmann	Bio-Reference Labs Passes the Test Small-cap lab-testing firm Bio-Reference Labs third-quarter results beat analysts projections by a decent margin, again proving it can compete with the big boys in the highly competitive New York metro area.
The Motley Fool September 6, 2007 Brian Lawler	NeurogesX Feels No Pain Investors reward the drugmaker for positive study results.
The Motley Fool September 6, 2007 David Lee Smith	Chesapeake Tries a New Bit With gas prices falling and credit tightening, Chesapeake Energy unveils its plans to deal with these hopefully temporary maladies.
The Motley Fool September 6, 2007 Tim Beyers	iMergent: A New Sin Stock? For all the controversy surrounding iMergent's business practices, this e-commerce specialist remains a moneymaker. Nevertheless, investors seem uninterested.
The Motley Fool September 6, 2007 Alyce Lomax	Starbucks: Made in China? Cheap is not always good. Investors have to wonder whether sourcing coffee from China is the brightest strategy for a company known for premium coffee.
The Motley Fool September 6, 2007 Toby Shute	Canadian Pacific Buys Like Buffett The Canadian railroad company has acquired Dakota, Minnesota & Eastern, the largest American regional railroad operator, in order to better access the bustling Midwestern coal, ethanol, and agricultural markets.
The Motley Fool September 6, 2007 Lawrence A. Rothman	Panera Needs a More Even Rise Panera Bread increases comps at its restaurants, but what good are increased sales without profitability? Investors want to see the company get its costs under control.
The Motley Fool September 6, 2007 Markos Kaminis	The Roller Coaster That Is Martek Martek BioSciences, producer of DHA fatty acid, continues its up-and-down pattern. Most recently, the stock prices collapsed after Q3 reports when the company found itself carrying excess capacity. Long-term investors, this may be a good time to buy.
The Motley Fool September 6, 2007 Brian Lawler	Amgen's Congressional Helpers Lawmakers push to ease restrictions on anemia compounds from Amgen and Johnson & Johnson. Investors, take note.
<Older 25951-25960 Newer> Return to current articles.